ProKidney reports Q2 net loss $38.5M, cash $431.5M, restarts Phase 3 trials

PROKIDNEY CORP.

Interim Phase 2 REGEN-007 data show kidney function stabilization for 18 months in diabetes/advanced CKD patients.
Manufacturing restarted; QP Declaration of Equivalence received in July; PROACT 1 and 2 trials resumed.
Closed $140M upsized equity offering in June, extending cash runway into mid-2026.
Cash & equivalents $431.5M at June 30, 2024 (vs $363.0M Dec 31, 2023).
R&D expenses $29.4M (Q2 2024) vs $26.4M (Q2 2023); net loss $38.5M vs $34.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.